US pharma major Merck (NYSE: MRK) has reported a Phase III success for Welireg (belzutifan) plus Keytruda (pembrolizumab) as ...

Scotland-based contract development and manufacturing organisation (CDMO) Symbiosis Services, a specialist in the GMP ...

United Therapeutics has announced that its long-term pivotal Phase III ADVANCE OUTCOMES study met its primary endpoint, with ralinepag reducing the risk of a clinical worsening event by 55% compared ...

Regulatory activity over the past week reflected steady committee throughput in Europe, a targeted oncology decision in the USA, and a cluster of safety and supply updates in the UK, Canada and ...

US pharma company Esperion Therapeutics has entered into an agreement to acquire Corstasis Therapeutics, a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient ...

California-based immunotherapy company 3T Biosciences has appointed Rebeca Villarreal-Barragan as head of clinical operations ...

ESTEVE CDMO, the global pure-play contract development and manufacturing organization (CDMO) specializing in high-quality ...

February 2026 saw robust M&A activity across the pharmaceutical and biotechnology sectors, marked by several high-value ...

Priovant Therapeutics today announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for brepocitinib for the treatment of dermatomyositis (DM) and has ...

Chinese drug developer Hua Medicine (HKEX: 2552) has won marketing approval in Hong Kong for Myhomsis (dorzagliatin), a first-in-class glucokinase activator for adults with Type 2 diabetes.

UK-based 4basebio, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, says it has promoted Christine Wolosin to chief commercial officer.

Germany’s Secarna Pharmaceuticals, which is focused on the discovery and development of best-in-class oligonucleotide therapeutics today announced the expansion of the existing scientific and ...